# A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study

> **NCT05614726** · NA · COMPLETED · sponsor: **The Center for Applied Health Sciences, LLC** · enrollment: 52 (actual)

## Conditions studied

- Microbiota
- Constipation
- Candida

## Interventions

- **DIETARY_SUPPLEMENT:** 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase

## Key facts

- **NCT ID:** NCT05614726
- **Lead sponsor:** The Center for Applied Health Sciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2022-03-17
- **Final completion:** 2022-03-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05614726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05614726, "A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05614726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*